In parallel with the above changes in TF binding and chromatin accessibility, the addition of IL-3 to FLT3i-treated AML cells substantially reversed the changes in the expression of FLT3i-sensitive genes. The gene discussed is IL3; the disease is acute myeloid leukemia.